The Consequences of Caronia: Impact On FDA’s Off-Label Regulation
This article was originally published in RPM Report
Executive Summary
The government has decided not to appeal the Second Circuit’s Caronia off-label promotion ruling – no doubt in part because of concerns about the broad reading of the First Amendment currently in favor at the Supreme Court. Officially, FDA has adopted a low-key response. Unofficially, agency officials – notably Bob Temple – are outraged by the ruling. What does Caronia mean for the future of FDA regulation and off-label prosecutions?
You may also be interested in...
FDA Reassessing Off-Label Policies To Address First Amendment Concerns
Guidance on scientific exchange is on the horizon; agency “carefully evaluating” existing advertising policies following recent court decisions.
Endo Lidoderm Settlements: “Golden Goose” Hatches Strong Case
Off-label promotion prosecutions are supposed to be much tougher in the post-Caronia period. However, it is not too hard for the government to make a compelling case when a marketing manager calls one off-label use the “golden goose” for a product line.
First Amendment Challenge Mulled As Amarin Seeks To Unchain ANCHOR Results
If Amarin can’t get its Vascepa expanded indication through FDA, it could try to get the courts to clarify the scope of free speech protections post-Caronia.